CYTOGEN LAUNCHES QUADRAMET TRIAL

Cytogen has initiated a multicenter Phase I clinical trial to investigate the use of Quadramet (samarium Sm-153 lexidronam) in combination with bortezomib for the treatment of multiple myeloma. The clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of bortezomib in combination with Quadramet.

The study is being conducted at four to six myeloma therapy research centers across the U.S. It is anticipated that up to 36 patients will be enrolled in the study.